Bridging the complexity of triple negative breast cancer care through multidisciplinary team approach

Abstract

Triple-negative breast cancer (TNBC) is still associated with a grave prognosis, especially compared to other breast cancer subtypes. TNBC carries a high risk of recurrence and distant metastasis, resulting in lower survival rates. Additionally, TNBC exhibits significant heterogeneity at the histopathological and multiomics levels, further complicating the development of effective treatments. While some TNBC subtypes may initially respond to chemotherapy, resistance frequently develops, increasing the risk of aggressive recurrence. The approach to TNBC management has undergone significant transformations in recent years, recognizing it as a heterogeneous disease with diverse biology and behavior. Chemotherapy remains the cornerstone of treatment for most TNBC cases, with the incorporation of PD-L1 CPS or immune cell (IC) scores and BRCA status being crucial for optimizing patient management. Besides the advancement of TNBC treatment, the multidisciplinary team also plays a key role in TNBC management, enabling improved diagnosis, treatment outcomes, disease monitoring, and management of adverse events.